Hepatitis C advancements provide new hope for patients

For the first time in nearly a decade, researchers have developed two new therapies to treat adult patients with chronic hepatitis C viral infection. The team of specialists at the UPMC Center for Liver Diseases has led the effort to evaluate these newer antiviral therapies, providing new hope for the medical management of hepatitis C.

These advancements, which recently were approved by the Food and Drug Administration, will improve the cure rate of the disease and shorten the duration of treatment.

The management of these medications can be complex for both patient care providers and their patients. The multidisciplinary expertise of the specialists at the UPMC Center for Liver Diseases, and their contributions to clinical trials, provide assistance for referring physicians and a new hope and reassurance for their patients.

For more information, visit www.upmc.com/Services/digestive/services/liver/Pages/HepatitisCTherapy.aspx.